Oppenheimer & Co. Inc. Takes $407,000 Position in BridgeBio Pharma, Inc. $BBIO

Oppenheimer & Co. Inc. acquired a new position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 7,845 shares of the company’s stock, valued at approximately $407,000.

Several other large investors have also recently added to or reduced their stakes in the business. Jones Financial Companies Lllp bought a new position in shares of BridgeBio Pharma in the first quarter worth $35,000. CWM LLC lifted its holdings in BridgeBio Pharma by 29.8% in the second quarter. CWM LLC now owns 6,830 shares of the company’s stock worth $295,000 after purchasing an additional 1,569 shares during the period. Allianz Asset Management GmbH grew its position in BridgeBio Pharma by 57.7% in the 2nd quarter. Allianz Asset Management GmbH now owns 12,300 shares of the company’s stock valued at $531,000 after buying an additional 4,500 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in BridgeBio Pharma in the 2nd quarter valued at about $229,000. Finally, Phoenix Financial Ltd. bought a new stake in shares of BridgeBio Pharma during the 2nd quarter worth about $209,000. 99.85% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have recently issued reports on the stock. The Goldman Sachs Group increased their price objective on shares of BridgeBio Pharma from $55.00 to $100.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Cantor Fitzgerald increased their price target on BridgeBio Pharma from $100.00 to $110.00 and gave the company an “overweight” rating in a research note on Thursday, October 30th. JPMorgan Chase & Co. lifted their price target on BridgeBio Pharma from $76.00 to $77.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. HC Wainwright upped their price objective on BridgeBio Pharma from $90.00 to $100.00 and gave the company a “buy” rating in a report on Tuesday. Finally, Raymond James Financial set a $89.00 target price on BridgeBio Pharma and gave the stock an “outperform” rating in a report on Thursday, February 12th. Twenty-two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $82.05.

Insider Activity

In related news, Director Randal W. Scott sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $75.46, for a total value of $754,600.00. Following the completion of the transaction, the director owned 11,589 shares of the company’s stock, valued at approximately $874,505.94. This trade represents a 46.32% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Neil Kumar sold 40,000 shares of BridgeBio Pharma stock in a transaction that occurred on Thursday, December 4th. The stock was sold at an average price of $74.40, for a total transaction of $2,976,000.00. Following the transaction, the chief executive officer owned 775,686 shares in the company, valued at approximately $57,711,038.40. The trade was a 4.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 176,121 shares of company stock valued at $13,009,631. Corporate insiders own 18.20% of the company’s stock.

BridgeBio Pharma Stock Down 2.5%

Shares of NASDAQ BBIO opened at $73.93 on Thursday. BridgeBio Pharma, Inc. has a 12 month low of $28.33 and a 12 month high of $84.94. The company has a market cap of $14.25 billion, a price-to-earnings ratio of -17.69 and a beta of 1.13. The business has a fifty day simple moving average of $75.73 and a 200-day simple moving average of $63.79.

Key BridgeBio Pharma News

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: HC Wainwright raised its price target to $100 and reiterated a Buy rating, signaling bullish analyst support that could underpin the stock. Benzinga
• Positive Sentiment: Several Wall Street firms maintain buy/overweight ratings and a median 6‑month target near $94, providing analyst-driven upside thesis for investors focused on BBIO’s pipeline and long-term growth. Analyst Coverage Summary
• Neutral Sentiment: BridgeBio will report Q4 and full‑year 2025 results after the close on Feb. 24 and host a 4:30 pm ET conference call — an event that can create short‑term volatility depending on revenue, cash burn and program updates. Earnings Release
• Neutral Sentiment: The company granted inducement RSUs to 34 new employees (76,701 aggregate shares) under Nasdaq rules; vesting schedules could modestly increase share-based compensation and future float. Inducement Grants
• Negative Sentiment: Multiple senior insiders sold stock on Feb. 17: Director Randal W. Scott (10,000 shares). These disclosed Form 4s reduce insider ownership and can spook investors when clustered. Scott Form 4
• Negative Sentiment: CFO Thomas Trimarchi sold 13,600 shares (≈$1.02M) and CAO Maricel Apuli sold 510 shares; clustered executive selling raises near‑term governance/ownership concerns for some investors. Trimarchi Form 4 Apuli Form 4
• Negative Sentiment: Data providers note a long history of insider sales (many officers have sold substantial blocks over recent months), which can weigh on sentiment even as analysts remain constructive. Insider/Analyst Summary

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.